Building Value Around a Testable Clinical Question

The near-term business case in SANS research is a measurement service, not a treatment claim. NASA needs studies that connect exposure, physiology, ocular structure, crew burden, and uncertainty. Investors need evidence that Gastronaut can provide this research capability before capital advances toward flight scale or a clinical proposition. Both groups benefit from a technical record that can be inspected when responsibility moves to the next decision maker.

The work begins with traceable, repeatable food and nutrient exposures that can be connected to NASA human-research measures. Clinical efficacy, flight qualification, procurement, and economic return remain questions for their respective evidence and decisions. This separation allows technical progress without asking a partial result to bear a conclusion it cannot support.

The decision need

The ocular-health synthesis contains 388 analysable studies from 3,375 unique records. It includes 100 human-spaceflight studies and 163 human ground-analog studies, the largest human evidence base in the ten-domain portfolio. Full-text retrieval did not run, so its quantitative observations describe indexed abstracts and cannot support a universal literature claim.

Physiological measurement is extensive. Integrated decision records are less common. Fifty-six studies applied lower body negative pressure or venoconstrictive cuffs, while five measured an ocular structural endpoint. Sixty-four of 301 intervention records stated a quantified time dose. The record includes six hours of lower body negative pressure per day across a 30-day bed-rest study (Lytle et al. 2023) and 4,032 scheduled countermeasure hours across a 47-participant trial (Moestl et al. 2025). Across 388 studies, the abstracts supplied no mass, volume, power, stowage, or equivalent-system-mass figure for a countermeasure.

The resulting questions are distinct. Mission planners need evidence of ocular effect and the operating burden associated with an intervention. Technology developers need evidence that a platform can produce a controlled exposure and retain a complete record. A research protocol can address both, provided that each conclusion keeps its own boundary.

A research service with bounded claims

Gastronaut is developing ORCA as a ground-stage cultivation system at approximately TRL 3 to 4. It has no flight or lunar operating history.

Proposed development work would measure production repeatability, fault classification, maintenance, and study-design performance under declared ground conditions. Variable-gravity performance, flight reliability, food safety, nutritional efficacy, ocular benefit, crew outcomes, and economic comparisons would each require evidence matched to the claim.

Within that boundary, Gastronaut can develop four linked capabilities: controlled crop production under declared environmental conditions; analytical confirmation of edible-material composition; a consumption and provenance record connected to each participant and timepoint; and integration of exposure data with biochemical, environmental, operational, and ocular measurements supplied by research partners.

The service unit is an answerable study exposure: specified material, produced and consumed under documented conditions, with a record suitable for clinical and mission analysis. A crop or chamber-hour becomes valuable when it contributes to that complete account.

Milestones for NASA and investors

Data integrity establishes the starting point. A complete crop cycle would preserve seed identity, environmental history, interventions, harvest, composition, offered mass, consumed mass, waste, labor, faults, and uncertainty. NASA could review whether that record supports a proposed human-research protocol. Investors could assess whether the company controls the information on which later claims depend.

Repeated ground cycles would test production repeatability within prespecified bounds. The resulting statement would concern production under those conditions, not participant health. Research integration would then test whether the exposure record remains synchronized with blood sampling, optical coherence tomography, environmental monitoring, medication records, adherence, and adverse-event reporting. This stage also makes operating burden visible.

Protocol readiness completes the sequence. NASA and research partners could choose an analog study, a flight feasibility study, redesign, or a stop decision. Investors could connect later capital to the same technical evidence while keeping procurement and return assumptions separate. The underlying record can support two decisions without merging their standards.

Cost belongs in the record early

Crew time appears in the ocular corpus even where system cost does not. Moestl and colleagues reported 4,032 scheduled countermeasure hours in a 47-participant, 30-day bed-rest trial, with 10.5 hours missed for medical reasons unrelated to the countermeasures (Moestl et al. 2025). Lytle and colleagues reported two three-hour lower body negative pressure sessions per day across 30 days in 12 participants (Lytle et al. 2023). These are protocol doses, not mission costs. They show why labor and tolerance belong beside biological outcomes.

An ORCA-supported study would report operator time, participant time, automated and manual tasks, maintenance, sampling, cleaning, failures, recovery, and data handling. Mass, volume, power, consumables, and stowage could be added under a declared system boundary. These measures would make later affordability comparisons answerable without treating a partial record as proof.

Confidence is high that the current corpus supports crew-time measurement as part of countermeasure research. Confidence is low in a complete system-cost comparison because the abstract-level record lacks the other cost currencies required for one. This is a measurement agenda rather than an economic conclusion.

The partnership proposition

Gastronaut proposes a scoped ground demonstration designed with NASA ocular-health, nutrition, food-safety, human-factors, and mission-analysis specialists. The parties would define one clinical research question, one controlled exposure, one comparator, and one ocular endpoint. Acceptance criteria would address exposure repeatability, data completeness, safety, operational burden, and uncertainty.

Success would mean that Gastronaut delivered a controlled and traceable research exposure within a protocol NASA can evaluate. It would not declare that ORCA mitigates SANS. Partnership, investment, and the next decision would rest on a defined technical record rather than an assumed clinical or commercial outcome. That is a credible basis for carrying the work forward.

References

Gastronaut. Ocular Health and Spaceflight-Associated Neuro-ocular Syndrome: Evidence Synthesis. Evidence version 22 Aug. 2026. Research synthesis.

Lytle, Jason R., et al. “Cardiovascular Responses to Daily Use of Lower Body Negative Pressure During 30 Days of Strict Head-Down Tilt Bed Rest.” Physiology, 2023. https://doi.org/10.1152/physiol.2023.38.s1.5735054.

Moestl, Sebastian, et al. “Mechanical Countermeasures for Spaceflight-Associated Neuro-ocular Syndrome During 30-Days of Head Down Tilt Bed Rest: Design, Implementation, and Tolerability.” Frontiers in Physiology, 2025. https://doi.org/10.3389/fphys.2025.1530783.